Clinical Trial News and Research

RSS

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US.

14 Nov 2014

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).

14 Nov 2014

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare mutations that shut down a single gene are linked to lower cholesterol levels and a 50 percent reduction in the risk of heart attack, according to new research from Washington University School of Medicine in St. Louis, the Broad Institute at Massachusetts Institute of Technology and Harvard, and other institutions.

14 Nov 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

UM researchers develop novel, family-focused, culturally-informed treatment for schizophrenia

Researchers at the University of Miami have developed a family-focused, culturally-informed treatment for schizophrenia (CIT-S). The program is one of the first to incorporate elements of the patient's cultural background as part of therapy.

11 Nov 2014

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London.

11 Nov 2014

Researchers refine diagnostic tools to predict treatment outcomes for children with neuroblastoma

Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.

11 Nov 2014

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

Peter Munk Cardiac Centre surgeons successfully implant novel heart device

A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

FDA approves ImThera Medical's investigational device exemption for pivotal study

ImThera Medical, Inc., a privately held global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study.

10 Nov 2014

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.

7 Nov 2014

Regenerative medicine may offer new standard of advanced treatment for foot and leg ulcers

These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.

7 Nov 2014

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.

7 Nov 2014

Clinical Trial News and Research

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

Study gives a roadmap for future brain cancer vaccines

Genticel completes patient enrollment for ProCervix phase II study

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Concordia Healthcare reports record revenues of 147% in third quarter 2014

UM researchers develop novel, family-focused, culturally-informed treatment for schizophrenia

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Researchers refine diagnostic tools to predict treatment outcomes for children with neuroblastoma

FDA accepts Amgen's evolocumab BLA for review

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Peter Munk Cardiac Centre surgeons successfully implant novel heart device

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

FDA approves ImThera Medical's investigational device exemption for pivotal study

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Regenerative medicine may offer new standard of advanced treatment for foot and leg ulcers

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery